Bluebird Soars After Trial Results for Blood Disease
This article is for subscribers only.
Shares of Bluebird Bio Inc. soared to an all-time high after the company said its experimental gene therapy helped four patients with an inherited blood disorder go without regular blood transfusions.
The four subjects had beta thalassemia major, a genetic condition in which the body doesn’t produce enough hemoglobin to carry oxygen around the circulatory system. The condition usually develops during infancy, causing weakness and organ problems and requiring blood transfusions.